The clinical investigator

, Volume 71, Supplement 8, pp S134–S136 | Cite as

Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study

  • C. Morisco
  • B. Trimarco
  • M. Condorelli
Conference on Coenzyme Q


The improved cardiac function in patients with congestive heart failure treated with coenzyme Q10 supports the hypothesis that this condition is characterized by mitochondrial dysfunction and energy starvation, so that it may be ameliorated by coenzyme Q10 supplementation. However, the main clinical problems in patients with congestive heart failure are the frequent need of hospitalization and the high incidence of life-threatening arrhythmias, pulmonary edema, and other serious complications. Thus, we studied the influence of coenzyme Q10 long-term treatment on these events in patients with chronic congestive heart failure (New York Heart Association functional class III and IV) receiving conventional treatment for heart failure. They were randomly assigned to receive either placebo (n = 322, mean age 67 years, range 30–88 years) or coenzyme Q10 (n = 319, mean age 67 years, range 26–89 years) at the dosage of 2 mg/kg per day in a 1-year double-blind trial. The number of patients who required hospitalization for worsening heart failure was smaller in the coenzyme Q10 treated group (n = 73) than in the control group (n = 118, P < 0.001). Similarly, the episodes of pulmonary edema or cardiac asthma were reduced in the control group (20 versus 51 and 97 versus 198, respectively; both P < 0.001) as compared to the placebo group. Our results demonstrate that the addition of coenzyme Q10 to conventional therapy significantly reduces hospitalization for worsening of heart failure and the incidence of serious complications in patients with chronic congestive heart failure.

Key words

Hospitalization Pulmonary edema Life-threatening Arrhythmias 


  1. 1.
    Cohn JN, Johnson G, Ziesche S et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303–310Google Scholar
  2. 2.
    Di Somma S, Carati L (1991) Efficacy of coenzyme Q in association with conventional therapy in the treatment of heart failure and ischemic heart disease. In: Biomedical and clinical aspects of coenzyme Q10. Elsevier, Amsterdam, pp 257–265Google Scholar
  3. 3.
    Folkers K, Vadhanavikit S, Mortensen SA (1985) Biochemical rationale and myocardial tissue data on the effective therapy for cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA (1985) 82:901–904Google Scholar
  4. 4.
    Langsjoen PH, Vadhanavikit S, Folkers K (1985) Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA 82:4240–44Google Scholar
  5. 5.
    Langsjoen PH, Langjoen PH, Folkers K (1991) Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. In: Biomedical and clinical aspects of coenzyme Q10. Elsevier, Amsterdam, pp 241–246Google Scholar
  6. 6.
    Littarru GP, Ho L, Folkers K (1972) Deficiency of coenzyme Q10 in human heart disease. I, II. Intern J Vit Nutr Res 42:291, 413Google Scholar
  7. 7.
    Mortensen SA, Kondrup J, Folkers K. (1991) Myocardial deficiency of coenzyme Q10 and carnitine in cardiomyopathy. Biochemical rationale for concomitant coenzyme Q10 and carnitine supplementation. In: Biomedical and clinical aspects of coenzyme Q10. Elsevier, Amsterdam, pp 269–281Google Scholar
  8. 8.
    Richardson PJ, Atkinson L (1980) In: Bolte H-D (ed) Myocardial biopsy. Diagnostic significance. Springer, Berlin Heidelberg New York, pp 97–101Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • C. Morisco
    • 1
  • B. Trimarco
    • 1
  • M. Condorelli
    • 1
  1. 1.Clinica Medica, Facoltà di Medicina e ChirurgiaUniversità degli Studi di Napoli “Federico II”Italy

Personalised recommendations